IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Examiner: Shiao, Rei Tsang

NAZARE, et al.

Art Unit: 1626

Application No.: 10/849,089

Filed: May 19, 2004

Title: Azaindole-derivatives as factor Xa inhibitors

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(b). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(b), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the autional stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any foes under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

⊠ (t	(b)) This Information Disclosure Statement is filed after the period set forth in 3					
		1.97(b), but is believed to be filed before the mailing date of a final action under §1.113				
		or a r	notice of allowance under §1.311, whichever occurs first.				
		(1)	The undersigned attorney certifies that each item of information contained in this				
			Information Disclosure Statement was cited in a communication from a foreign				
			patent office in a counterpart foreign application not more than three months prior				
			to the filing of this statement;				
		(2)	The undersigned attorney certifies that no item of information contained in this				
			Information Disclosure Statement was cited in a communication from a foreign				

statement; or

(3) This Information Disclosure Statement is accompanied by payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this

Respectfully submitted,

Jiang Lin, Reg. No. 51,065 Attorney/Agent for Applicant

Feb. 22, 2.007

Dated

sanofi-aveatis U.S. LLC
U.S. Patent Operations
Route #020-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-382
Telefax (908) 231-3626
Telephone (908) 231-3626

Please type a plus sign (+) inside this tox →	PTO/\$B/08A (10-95)	
	Approved for use through 10/31/99 CMB 0651-0031 Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE	
Under the Paperwork Reduction Act of 1995, no persons are required to respon	aid to a collection of information unless it contains a valid OMB control number.	

Substitu	te for form 1449A/PTC	,		Complete if Known		
				Application Number	10/849,089	
			SCLOSURE	Fiting Date	05-19-2004	
STA	TEMENT B	Y	APPLICANT	First Named Inventor	NAZARÉ, et al.	
				Group Art Unit	1626	
	(use as many she	ස්ථ ය	s necessary)	Examiner Name	SHIAO, Rei Tsang	
Sheet	1	of	1	Attomey Docket Number	DEAV2003/0033 - US - NP	

	U.S. PATENT DOCUMENTS							
Exactines Indials*	Cite	U.S. Paten	t Document	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines,		
	No.	Number (stanown)		of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear		
		7,135,469		Donald J. PINTO	11-14-2006			
_	_							
-	_				-			
-	_							
	_		_		+			
			-		_			
	_		_					
-	_		-					
	-							
-	_		-		 			
$\overline{}$			-					
\neg								

			FORE	IGN PATENT DOCUMENT	TS		
Citie No.1		Foreign Patent Do		Name of Batestee or	Cate of Publication of	Pages, Columna, Lines,	П
	Ottoe ³	Number ⁴	Kind Code? (FAXXwr)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevent Figures Appear	т•
	-		\rightarrow				П
_			-		 		Н
	\vdash		-				Н
							Н
_	-		\Box				П
	\vdash				-		Н
		C159	C156	Citie Foreign Patent Document	City Foreign Patent Document Name of Patentee or	Cited Document Cited Document	City City Che Che Che Che Che Che Che Ch

Examiner	Date
Signature	Considered
"EXAMINER: Initial if reference considered, whether or not obtains a considered. Include conv of this form with peut communication to an	s in conformance with MPEP 609. Draw line through clastion if not in conformance and officiall

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chair Individual Control, Platest and Trademark Office, Washington, DC 20239 DO NOT SEND PESS OR CONVEILED FORMS TO THIS ADDRESS. SEND IT. Assistant Commissioner for Paintry, Washington, DC 20239 DO NOT SEND PESS OR CONVEILED FORMS TO THIS ADDRESS. SEND IT. Assistant Commissioner for Paintry, Washington, DC 20239 DO NOT SEND PESS OR CONVEILED FORMS TO THIS ADDRESS. SEND IT.

^{*}Unique outlion designation number: *Spin attached Kinds et U.S. Patent Document; *Elizar Office that count of to document; by the two-laters on (HVPO Standard ST3, *F Fra. Injustace pointed document, by the two-laters of the region of the import must provide the rend in an injust of the import must provide the rend in market of the patent document. *Event of document by the appropriate synthetis an indicated on the document over WPO Standard ST. 16 if possible **Appear to to place a deck must have the English Injuspacy Translation is attached.